Table 1.
Characteristics of patients with ARD and CG at 6 weeks after second Sinovac-CoronaVac (D69)
| ARD (n = 828) | CG (n = 207) | p-value | |
|---|---|---|---|
| Demographics | |||
| Current age, years | 51 (41-60) | 51 (42-60) | 0.898 |
| Age ≥60 years | 213 (25.7) | 54 (26.1) | 0.915 |
| Male sex | 204 (24.6) | 51 (24.6) | >0.999 |
| Caucasian ethnicity | 425 (51.3) | 95 (45.9) | 0.163 |
| ARD | |||
| Rheumatoid arthritis | 228 (27.5) | — | — |
| Axial spondyloarthritis | 196 (23.7) | — | — |
| Systemic lupus erythematosus | 206 (24.9) | — | — |
| Primary vasculitis | 51 (6.2) | — | — |
| Systemic sclerosis | 36 (4.3) | — | — |
| Primary Sjögren syndrome | 36 (4.3) | — | — |
| Idiopathic inflammatory myopathy | 40 (4.8) | — | — |
| Current therapy | |||
| Prednisone | 302 (36.5) | — | — |
| Prednisone dose, mg | 5 (5-40) | — | — |
| Prednisone ≥10 mg/day | 116 (14.0) | ||
| Prednisone ≥20 mg/day | 27 (3.3) | — | — |
| Hydroxychloroquine | 239 (28.9) | — | — |
| Sulfasalazine | 72 (8.7) | — | — |
| Immunosuppressive drugs | 513 (62.0) | — | — |
| Methotrexate | 209 (25.2) | — | — |
| Leflunomide | 115 (13.9 | — | — |
| Mycophenolate mofetil | 109 (13.2) | — | — |
| Azathioprine | 90 (10.9) | — | — |
| Tofacitinib | 20 (2.4) | — | — |
| Cyclophosphamide | 6 (0.7) | — | — |
| Tacrolimus | 10 (1.2) | — | — |
| Cyclosporine | 9 (1.1) | — | — |
| Biologic therapy | 296 (35.7) | — | — |
| TNF inhibitor | 126 (15.2) | — | — |
| Abatacept | 43 (5.2) | — | — |
| Tocilizumab | 46 (5.6) | — | — |
| Belimumab | 26 (3.1) | — | — |
| Secukinumab | 34 (4.1) | — | — |
| Rituximab | 17 (2.1) | — | — |
| Ustekinumab | 4 (0.5) | — | — |
Results are expressed in medians (interquartile range) and n (%). Continuous data were compared using Mann-–Whitney test, and categorical variables with the chi-square or Fisher’s exact tests, as appropriate, always as two-sided analyses, without adjustments for multiple comparisons.
ARD autoimmune rheumatic diseases, CG control group.